CreoSG Co.,Ltd. Stock

Equities

A040350

KR7040350001

Software

End-of-day quote Korea S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
1,000 KRW 0.00% Intraday chart for CreoSG Co.,Ltd. +19.76% +93.80%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 9.78B 7.17M Sales 2023 9.76B 7.15M Capitalization 64.8B 47.5M
Net income 2022 -10.44B -7.65M Net income 2023 -11.74B -8.61M EV / Sales 2022 10.9 x
Net Debt 2022 22.59B 16.56M Net Debt 2023 2.54B 1.86M EV / Sales 2023 6.9 x
P/E ratio 2022
-8.01 x
P/E ratio 2023
-5.54 x
Employees 33
Yield 2022 *
-
Yield 2023
-
Free-Float 67.41%
More Fundamentals * Assessed data
Dynamic Chart
CUROCOM Co., Ltd. announced that it has received KRW 8.5 billion in funding from CUROHOLDINGS Co., Ltd. CI
CUROCOM Co., Ltd. announced that it expects to receive KRW 8.5 billion in funding from CUROHOLDINGS Co., Ltd. and other investor CI
CUROCOM Co., Ltd.(KOSDAQ:A040350) dropped from S&P Global BMI Index CI
CUROCOM Co., Ltd. announced that it has received KRW 6 billion in funding CI
KIB Private Equity Co., Ltd, KIB CURO Second Acquisition Purpose Company completed the acquisition of a 37.359021% stake in Curo Co.,Ltd. from CUROCOM Co., Ltd., GNCO Co., Ltd., Q Capital Partners Co., Ltd., Qyuro F & B Co., Ltd. and Dongjun Kim CI
CUROCOM Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
KIB Private Equity Co., Ltd, KIB CURO Second Acquisition Purpose Company agreed to acquire a 37.359021% stake in Curo Co.,Ltd. from CUROCOM Co., Ltd., GNCO Co., Ltd., Q Capital Partners Co., Ltd., Qyuro F & B Co., Ltd. and Dongjun Kim for KRW 51.9 billion. CI
CUROCOM Co., Ltd. announced that it has received KRW 6 billion in funding CI
CUROCOM Co., Ltd. announced that it expects to receive KRW 6 billion in funding CI
CUROCOM Co., Ltd. announced that it has received KRW 8.399998653 billion in funding from Curo Holdings Co., Ltd., Q Capital Partners Co., Ltd. CI
CUROCOM Co., Ltd. announced that it expects to receive KRW 8.399998653 billion in funding from Curo Holdings Co., Ltd., Q Capital Partners Co., Ltd. CI
Sumagen Co., Ltd. announced that it has received KRW 11.864430381 billion in funding from CUROCOM Co., Ltd. CI
Sumagen Co., Ltd. announced that it expects to receive KRW 11.864430381 billion in funding from CUROCOM Co., Ltd. CI
CUROCOM Co.,Ltd. announced that it has received KRW 3 billion in funding CI
Qyuro F & B Co., Ltd. announced that it has received KRW 5.4 billion in funding from CUROCOM Co., Ltd. and other investors CI
More news
1 week+19.76%
Current month+19.76%
1 month+140.38%
3 months+122.72%
6 months+112.31%
Current year+93.80%
More quotes
1 week
817.00
Extreme 817
1 026.00
1 month
408.00
Extreme 408
1 026.00
Current year
405.00
Extreme 405
1 026.00
1 year
405.00
Extreme 405
1 026.00
3 years
405.00
Extreme 405
2 020.00
5 years
405.00
Extreme 405
3 180.00
10 years
405.00
Extreme 405
5 400.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 04-01-29
Comptroller/Controller/Auditor 50 10-03-24
Members of the board TitleAgeSince
Director/Board Member 54 15-03-23
Chief Executive Officer 54 04-01-29
Director/Board Member 64 -
More insiders
Date Price Change Volume
24-05-07 1,000 0.00% 1 366 681
24-05-07 1,000 +6.95% 1,367,464
24-05-03 935 -3.01% 1,734,515
24-05-02 964 +15.45% 5,387,206
24-04-30 835 -0.60% 1,417,549

End-of-day quote Korea S.E., May 07, 2024

More quotes
CreoSG Co Ltd, formerly Curocom Co Ltd, is a Korea-based company mainly engaged in solution business and distribution business. The Company operates through three segments. The Solutions Business segment is engaged in the development and provision of financial consulting and software for financial institutions. Additionally, the segment is engaged in the supply of core banking solutions BANCS-K framework and BANCS-K Package to banks and other financial institutions. The Distribution Business segment is engaged in the distribution business of computers, laptops, printers, and multi-function printers. The New Drug and Vaccine Development Business segment is engaged in the development of vaccines for acquired immunodeficiency syndrome(AIDS), corona virus disease 19 (COVID-19) vaccine and other infectious diseases, and research and development of super antibiotics for Staphylococcus aureus.
More about the company
  1. Stock Market
  2. Equities
  3. A040350 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW